Search

Displaying results 1581 - 1590 of 10000 in total
  1. Drug

    Sulfamethizole

    go.drugbank.com/drugs/DB00576
    ApprovedVet approved

    A sulfathiazole antibacterial agent.

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: S- URISTIX 500 MG CAPSULAS, S*ORIPOL FORTE - SULFAMETIZOL 500 MG CAPSULAS
  2. Drug

    Guanfacine

    go.drugbank.com/drugs/DB01018
    ApprovedInvestigational

    Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: GUAGO 1 MG UZATILMIŞ SALIMLI TABLET, 7 ADET, GUAGO 2 MG UZATILMIŞ SALIMLI TABLET, 7 ADET
  3. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Moroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein [L41170]. … Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function.

    Products: REFACTO AF 500 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUC FLAKON, 1 ADET, REFACTO AF 1000 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADET
  4. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ACOMPLIA ® COMPRIMIDOS RECUBIERTOS20 MG
  5. Drug

    Oxiconazole

    go.drugbank.com/drugs/DB00239
    Approved

    Oxiconazole is an antifungal agent that is commonly found in topical formulations. It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ri...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]
  6. Drug

    Mebrofenin

    go.drugbank.com/drugs/DB15779
    Approved

    Products: POLTECHMBRIDA 20 MG. KIT PARA LA PREPARACION RADIOFARMACEUTICA, Kit for the Preparation of Technetium Tc 99m Mebrofenin
  7. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

    Products: CARBIMAZOLE 5 TABLET 5 mg, CAMAZOL TABLET 5 mg
  8. Drug

    Quinidine

    go.drugbank.com/drugs/DB00908
    Approved

    [A38016] Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. … However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.[A250050]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersSynonyms: (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol, (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol
  9. Drug

    Glycine

    go.drugbank.com/drugs/DB00145
    ApprovedInvestigationalNutraceuticalVet approved

    A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

    Mixtures: PEDASEL %10 AMİNO ASİT ÇÖZELTİSİ, 100 ML, PRIMENE %10 İNFÜZYONLUK PEDİYATRİK AMİNOASİT ÇÖZELTİSİ, 100 MLProducts: CAREDO Treating Gingivitis Toothpastes 100g, CAREDO Repair Cracked Teeth Toothpastes 100g
  10. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: ROPINIROL-NEURAX 5 MG, ROPINIROL AL 5 MG FILMTABL